JP2018519300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519300A5 JP2018519300A5 JP2017566806A JP2017566806A JP2018519300A5 JP 2018519300 A5 JP2018519300 A5 JP 2018519300A5 JP 2017566806 A JP2017566806 A JP 2017566806A JP 2017566806 A JP2017566806 A JP 2017566806A JP 2018519300 A5 JP2018519300 A5 JP 2018519300A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 27
- 229940126062 Compound A Drugs 0.000 claims 20
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 15
- 210000003719 b-lymphocyte Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 230000036210 malignancy Effects 0.000 claims 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 102000003929 Transaminases Human genes 0.000 claims 1
- 108090000340 Transaminases Proteins 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 210000001280 germinal center Anatomy 0.000 claims 1
- 210000001102 germinal center b cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- SEJLPXCPMNSRAM-GOSISDBHSA-N CC#CC(N(CC1)C[C@@H]1N(c1ncnc(N)c1N1c(cc2)ccc2Oc2ccccc2)C1=O)=O Chemical compound CC#CC(N(CC1)C[C@@H]1N(c1ncnc(N)c1N1c(cc2)ccc2Oc2ccccc2)C1=O)=O SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 1
- IFSDAJWBUCMOAH-UHFFFAOYSA-N CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)Nc1ncnc2c1nc[nH]2 Chemical compound CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)Nc1ncnc2c1nc[nH]2 IFSDAJWBUCMOAH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183699P | 2015-06-23 | 2015-06-23 | |
| US62/183,699 | 2015-06-23 | ||
| US201562200610P | 2015-08-03 | 2015-08-03 | |
| US62/200,610 | 2015-08-03 | ||
| US201562263454P | 2015-12-04 | 2015-12-04 | |
| US62/263,454 | 2015-12-04 | ||
| PCT/US2016/038763 WO2016209961A1 (en) | 2015-06-23 | 2016-06-22 | Combination therapies for treating b-cell malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519300A JP2018519300A (ja) | 2018-07-19 |
| JP2018519300A5 true JP2018519300A5 (https=) | 2019-06-06 |
| JP6785804B2 JP6785804B2 (ja) | 2020-11-18 |
Family
ID=56497846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566806A Expired - Fee Related JP6785804B2 (ja) | 2015-06-23 | 2016-06-22 | Ｂ細胞悪性腫瘍を治療するための組合せ療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180353512A1 (https=) |
| EP (1) | EP3313405A1 (https=) |
| JP (1) | JP6785804B2 (https=) |
| TW (1) | TW201713344A (https=) |
| WO (1) | WO2016209961A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180207164A1 (en) * | 2015-08-03 | 2018-07-26 | Gilead Sciences, Inc. | Combination therapies for treating cancers |
| CA3101323A1 (en) * | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| CA3158321A1 (en) * | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
| KR20210115375A (ko) * | 2020-03-12 | 2021-09-27 | 보령제약 주식회사 | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 |
| WO2023030437A1 (zh) * | 2021-09-01 | 2023-03-09 | 江苏恒瑞医药股份有限公司 | 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途 |
| CN114831991B (zh) * | 2022-06-10 | 2024-02-06 | 陕西科技大学 | Gsk2334470用于制备抗真菌药物及其增效剂的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| BR112012030711B1 (pt) * | 2010-05-31 | 2020-10-13 | Ono Pharmaceutical Co. Ltd | derivado de purinona |
| DK2786996T3 (en) * | 2011-11-29 | 2016-12-19 | Ono Pharmaceutical Co | Hydrochloride PURINONDERIVAT |
| SG11201509842SA (en) * | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| EA201691169A1 (ru) * | 2013-12-05 | 2016-09-30 | Асерта Фарма Б.В. | Терапевтическая комбинация ингибитора pi3k и ингибитора btk |
| MA40596B1 (fr) * | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
-
2016
- 2016-06-22 WO PCT/US2016/038763 patent/WO2016209961A1/en not_active Ceased
- 2016-06-22 EP EP16741427.5A patent/EP3313405A1/en not_active Withdrawn
- 2016-06-22 JP JP2017566806A patent/JP6785804B2/ja not_active Expired - Fee Related
- 2016-06-22 US US15/739,049 patent/US20180353512A1/en not_active Abandoned
- 2016-06-23 TW TW105119835A patent/TW201713344A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519300A5 (https=) | ||
| JP2017008088A5 (https=) | ||
| JP2017518334A5 (https=) | ||
| JP2019526595A5 (https=) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| JP2018184417A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| JP2019506403A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| JP2015533176A5 (https=) | ||
| SI3157932T1 (en) | Sodium (2R, 5S, 13AR) -7,9-dioxo-10 ((2,4,6-trifluorobenzyl) carbamoyl) -2,3,4,5,7,9,13,13A-octahydro- 5-methanopyrido (1'2 ': 4.5) pyrazino (2,1-B) oxazepine-8-oleate | |
| JP2015038149A5 (https=) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| JP2014510729A5 (https=) | ||
| JP2012082234A5 (https=) | ||
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| JP2014524469A5 (https=) | ||
| JP2018503610A5 (https=) | ||
| JP2011529968A5 (https=) | ||
| JP2018090566A5 (https=) | ||
| JP2016523858A (ja) | がんを治療するためのｂｔｋ阻害剤とフルオロウラシルとの併用 | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| JP2020514344A5 (https=) | ||
| JP2015502926A5 (https=) |